Subscribe Become an Author Add Company Sign Up Log In

Biopharma news


Exyte and Univercells Technologies Combine Аorces for Rapid Deployment of Vaccine Production Plants in the Wake of the COVID-19 Pandemic

   by White Matter Communications    72
  • Exyte offers the new ExyCellR modular technology for fast-track construction of biologicals production facilities compliant with the current good manufacturing practice (cGMP).
  • Univercells Technologies delivers the integrated NevoLine™ biomanufacturing platform, including scale-X™ bioreactors, for low footprint and economic large-scale production of viral products.
  • The combined offer enables users to rapidly deploy prefabricated GMP vaccine manufacturing facilities in response to new disease outbreaks.

Pulmotect receives FDA approval to commence two Phase-2 trials targeting COVID-19

   by Dana Summers    42
Pulmotect receives FDA approval to commence  two Phase-2 trials targeting COVID-19

Houston, TX (May 2020) Pulmotect, Inc., a clinical-stage biotechnology company, has received approval from the U.S. Food & Drug Administration (FDA) to initiate two COVID-19 Phase-2 clinical trials of its innate immune-stimulating drug PUL-042. The Company plans to start accrual within the next week at up to twenty U.S. sites. The trials are for the prevention of infection with SARS-CoV-2 and the prevention of disease progression in patients with early COVID-19 disease. Funding for the trials came from the final closing of the Company’s offering of Series B Preferred stock in March.

Quartic.ai and Bright Path Labs Partner to Deliver AI Powered Continuous Manufacturing of Critical APIs for Life-Saving Medicines

   by Broadpath    66
Quartic.ai and Bright Path Labs Partner to Deliver AI Powered Continuous Manufacturing of Critical APIs for Life-Saving Medicines

SAN JOSE, Calif. (May 6, 2020 ) - Quartic.ai, a manufacturing AI and IIoT platform supplier, and Bright Path Laboratories, Inc. (Bright Path Labs), a provider of continuous flow reactor technologies, signed an agreement to develop an AI powered continuous manufacturing platform for active pharmaceutical ingredients (APIs) and other small molecule drugs using Bright Path Labs’ continuous bioreactor and the Quartic.ai smart manufacturing technology.

Challenges in Supply and Partner-Sourcing for Stem-Gene – Clinical Trial Supply – A Virtual Experience

   by Arena International Events Group    87
Challenges in Supply and Partner-Sourcing for Stem-Gene – Clinical Trial Supply – A Virtual Experience

London – On Tuesday, (12th May) CTS Virtual (https://arena-international.com/ctsvirtual/),  will host new key sessions on Clinical Trial Supply 2020 Trends, Stem-gene Clinical Trials and many more.

As modern medicine advances, the global clinical supply chain needs to keep up, and the expanding market for stem-cell and gene therapy is making this increasingly complex for companies doing research and development in these areas. The therapeutic potential for stem-cell and gene products is vast, with targeted personalized medicine to suit the individual needs of sick patients, but running clinical supply operations in these fields can come at a high cost and requires detailed planning.

Pharma Companies Join Forces to Train AI for Drug Discovery Using Blockchain

   by Andrii Buvailo    6622
Pharma Companies Join Forces to Train AI for Drug Discovery Using Blockchain

The newly organized research project “MELLODDY” (Machine Learning Ledger Orchestration for Drug Discovery), involving ten large pharma companies and seven technology providers, is that kind of deals which can catalyze a transition of the pharmaceutical industry to a new level -- a “paradigm shift”, as one might refer to it in terms of Thomas Kuhn’s “The Structure of Scientific Revolutions”.

The project aims at developing a state-of-the-art platform for collaboration, based on Owkin’s blockchain architecture technology, which would allow collective training of artificial intelligence (AI) algorithms using data from multiple direct pharmaceutical competitors, without exposing their internal know-hows and compromising their intellectual property -- for the collective benefit of everyone involved.